Researchers find trigger for killer protein in cancer

[Guest guest]

Aileron Therapeutics has made a new discovery and has been able to rapidly

advance multiple Stapled Peptide programs; they have built a broad and growing

product candidate pipeline. The Company is initially focusing its efforts on

cytosolic and nuclear targets for indications within HEMATOLOGICAL CANCERS and

solid cancers. Thus far, the preclinical data AILERON has generated has been

compelling: At the 2008 American Association for Clinical Cancer Research (AACR)

annual meeting, AILERON presented preclinical data showing excellent in vitro

and in vivo efficacies for Stapled Peptide compounds in multiple cancer models.

Aileron, and its collaborators, are also progressing programs to treat

infectious disease, metabolic disease and immune/inflammatory diseases.

http://www.aileronrx.com./programs.php

AILERON's Stapled Peptide drugs provide the opportunity to greatly expand the

number of " druggable " targets by targeting the thousands of intracellular

protein-protein interactions that can not be functionally modulated by current

therapeutics. Leveraging these unique attributes, AILERON is creating a new

paradigm in drug discovery and development.

http://www.aileronrx.com./science.php

----------------------------------------

Q-RT-PCR Testing & Ph+ CMLEmerging evidence suggests that, in conjunction with

achieving a hematologic response and a cytogenetic response, achieving a

molecular response to therapy may correlate with improved progression-free

survival in patients with Ph+ CML.1Quantitative reverse-transcriptase polymerase

chain reaction (Q-RT-PCR) is the best way to assess molecular response in

patients with Ph+ CML.2 Q-RT-PCR enables extremely low levels of Bcr-Abl RNA

transcripts to be monitored over time.2Timely access to consistent and easily

interpretable Q-RT-PCR results is important for:Assessing whether a patient with

Ph+ CML has achieved or is trending toward a desired response to therapy2

Helping to ensure that a patient's treatment is optimized over time2 A group of

international experts in Ph+ CML is currently working to establish a uniform

standard for performing Q-RT-PCR and reporting and interpreting the results.2

These experts recommend that Q-RT-PCR be performed at least every 3 months to

assess response to therapy.2

Look for more information on standardized PCR testing offered through CML

AllianceT.

1.. Druker BJ et al. N Engl J Med. In press.

2.. T, Deininger M, Hochhaus A, et al. Monitoring CML patients

responding to treatment with tyrosine kinase inhibitors: review and

recommendations for harmonizing current methodology for detecting BCR-ABL

transcripts and kinase domain mutations and for expressing results. Blood.

2006;108(1):28-37. [p 28]

http://www.cmlalliance.com/health-care-professional/qrtpcr-testing-ph-cml.jsp?si\

te=google & irmasrc=none & source=01030 & campaign=CML-900127

3.. ______________________________________________

Glivec, a once-a-day pill sold as Gleevec in the United States, is Novartis's

second-biggest seller, raking in $3.1 billion in 2007. ata from a Phase III

study showed patients with newly diagnosed CML receiving a higher initial dose

of Glivec showed better early responses than those taking smaller quantities.

However, the difference between the two arms of the study -- those taking 800

milligrams a day and others taking 400 mg -- " was not statistically

significant, " Novartis said.

http://www.reuters.com/article/rbssPharmaceuticals%20-%20Diversified/idUSL135144\

3720080613

_____________________________________________________________________

" Because BAX lies at the crossroads of the cell's decision to live or die, drugs

that directly activate BAX could kill diseased cells like in cancer and

BAX-blocking drugs could potentially prevent unwanted cell death, such as in

heart attack, stroke, and neurodegeneration, " Walensky said in a statement.

http://www.caring4cancer.com/go/cancer/news?NewsItemId=20081023elin014.xml

For your reading files,

Lottie